Novel combinations of targeted therapy for the treatment of MLL leukaemia

急性白血病中涉及MLL基因的染色体断裂导致的不良预后在二十多年中没有明显改变。这一事实突出表明，迫切需要确定和开发治疗这种疾病的新的治疗药物。该项目旨在了解导致这种侵袭性疾病的启动和维持的机制。然后，我们将利用这些洞察力来开发合理的治疗剂组合。

The poor prognosis conferred by chromosome breaks involving the MLL gene in acute leukaemia has not significantly changed in over twenty years. This fact highlights the urgent need to identify and develop novel therapeutic agents for this disease. This project will aim to understand the mechanisms leading to the initiation and maintenance of this aggressive disease. We will then use these insights to develop a rational combination of therapeutic agents.